Fabtech Technologies IPO Day 2: Check Subscription Status & Key Highlights
The Fabtech Technologies IPO enters its second day of subscription today, 30 September 2025. Till the end of day 1, the IPO received a total subscription of 0.70 times. The bidding window is scheduled to close on October 1, 2025.
Fabtech Technologies IPO: Issue Details
The Fabtech Technologies IPO is a book-building issue of ₹230.35 crores, consisting entirely of a fresh issue of 1.21 crore shares. The price band is set between ₹181 and ₹191 per share. The basis of allotment will be finalised by October 3, 2025, and the tentative listing date on NSE and BSE is October 7, 2025.
The book-running lead manager for the IPO is Unistone Capital Private Limited, while Bigshare Services Private Limited serves as the registrar for the issue.
Fabtech Technologies IPO Day 2 Subscription Status
[30-September-2025 10:12:00]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.77 |
|
Non-Institutional Investors |
0.52 |
|
Retail Individual Investors (RIIs) |
0.80 |
|
Employees |
0.62 |
|
Total |
0.74 |
Fabtech Technologies IPO Day 1 Subscription Status
[29-September-2025 17:00:00]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.77 |
|
Non-Institutional Investors |
0.46 |
|
Retail Individual Investors (RIIs) |
0.70 |
|
Employees |
0.54 |
|
Total |
0.70 |
Utilisation of IPO Proceeds
The net proceeds from the fresh issue will be used to fund the following objectives:
- Fund working capital requirements
- Pursue inorganic growth initiatives via acquisitions
- General corporate purposes
Fabtech Technologies Business Overview
Fabtech Technologies delivers end-to-end project turnkey engineering services, from concept development to regulatory compliance and facility validation, to the pharmaceutical, biotechnology, and healthcare industries. The company has developed a strong presence across more than 60 countries, including key markets in Asia, Africa, the Middle East, Europe, Latin America, and others.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.